CytoMed Therapeutics Ltd.
CytoMed Therapeutics Ltd. is a Singapore-based biopharmaceutical company focused on developing cell-based immunotherapies for cancer and other serious diseases. Its current pipeline centers on innate immune cell and stem cell-based technologies, including gamma delta T-cell, natural killer T-cell, and pluripotent stem cell platforms designed to support novel therapeutic candidates. The company’s work includes research, development, processing, and banking of cells, with an emphasis on allogeneic approaches that use donor-derived materials. CytoMed Therapeutics Ltd. operates primarily in Singapore and Malaysia, serving the growing biotechnology and advanced therapy markets in Asia. Its role in the financial market is tied to the high-potential but research-intensive biopharmaceutical sector, where progress depends on clinical development, regulatory milestones, and platform innovation.
$0.88
+$0.01 (+1.15%)
EOD Oct 16, 2026
The business is unprofitable at the operating level (-1307.60% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 366.7% YoY with margins expanding 3196.7pp.
ROIC dropped from -23.33% to -39.79%, capital efficiency is deteriorating. Negative free cash flow of -SGD 4M. The business is consuming cash, not generating it.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
SGD 324K
▲ +366.7% YoY
Net Income (TTM)
-SGD 4M
▼ -58.5% YoY
Op. Margin
-1307.60%
▲ +3196.7pp YoY
ROIC
-39.79%
▼ -16.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-SGD 4M
▼ -4.7% YoY
Op. Cash Flow (TTM)
-SGD 4M
▼ -36.4% YoY
Net Debt
-SGD 2M
Net Cash Position
Cash & Equiv.
SGD 2M
Continue Research
Is CytoMed Therapeutics (GDTC) overvalued?
CytoMed Therapeutics (GDTC)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, CytoMed Therapeutics scores 20/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is CytoMed Therapeutics a high-quality business?+
CytoMed Therapeutics scores 20 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -1,307.6% operating margin and a -39.8% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is CytoMed Therapeutics a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh GDTC's valuation and scores 20/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Biotechnology
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.